Pessayre D, Allemand H, Benhamou J P
Nouv Presse Med. 1977 Oct 22;6(35):3209-19.
Drug metabolism may be impaired in patients with hepato-biliary diseases. Hepatocellular failure may decrease the rate of drug biotransformation; cholestasis may decrease 1) the absorption of lipid soluble drugs, 2) the rate of drug biotransformation, and 3) the biliary excretion of drugs. Activity and/or toxicity are modified variously as either the drug or a metabolite of it is the active and/or toxic compound. Although there is an obvious need for an adapted posology in patients with liver diseases, only suggestions can be drawn from presently limited data.
肝胆疾病患者的药物代谢可能会受损。肝细胞功能衰竭可能会降低药物生物转化的速率;胆汁淤积可能会降低:1)脂溶性药物的吸收;2)药物生物转化的速率;3)药物的胆汁排泄。药物及其代谢产物中无论是哪一种是活性和/或毒性化合物,其活性和/或毒性都会受到不同程度的影响。虽然显然需要为肝病患者调整用药剂量,但目前有限的数据只能给出一些建议。